Pamir Consulting, LLC’s Post

The BIOSECURE Act (the “Act”), introduced by members of the House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party (“House Select Committee on the CCP”) on January 25, 2024, targets certain biotechnology companies that are headquartered in foreign adversary countries. The Act prohibits U.S. government agencies from acquiring biotechnology equipment or services produced or provided by a biotechnology company of concern. Additionally, there have been calls on the U.S. Department of Defense, Commerce, and Treasury to investigate biotechnology company WuXi Apptec and its subsidiary WuXi Biologics. Members of our International Trade and Government Relations practices have recently authored this thought leadership article which summarizes the proposed Act's background, goals, targets, and more. Please be sure to click the link below to learn more.

The BIOSECURE Act (the “Act”), introduced by members of the House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party (“House Select Committee on the CCP”) on January 25, 2024, targets certain biotechnology companies that are headquartered in foreign adversary countries. The Act prohibits U.S. government agencies from acquiring biotechnology equipment or services produced or provided by a biotechnology company of concern. Additionally, there have been calls on the U.S. Department of Defense, Commerce, and Treasury to investigate biotechnology company WuXi Apptec and its subsidiary WuXi Biologics. Members of our International Trade and Government Relations practices have recently authored this thought leadership article which summarizes the proposed Act's background, goals, targets, and more. Please be sure to click the link below to learn more.

The BIOSECURE Act (the “Act”), introduced by members of the House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party (“House Select Committee on the CCP”) on January 25, 2024, targets certain biotechnology companies that are headquartered in foreign adversary countries. The Act prohibits U.S. government agencies from acquiring biotechnology equipment or services produced or provided by a biotechnology company of concern. Additionally, there have been calls on the U.S. Department of Defense, Commerce, and Treasury to investigate biotechnology company WuXi Apptec and its subsidiary WuXi Biologics. Members of our International Trade and Government Relations practices have recently authored this thought leadership article which summarizes the proposed Act's background, goals, targets, and more. Please be sure to click the link below to learn more.

The BIOSECURE Act (the “Act”), introduced by members of the House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party (“House Select Committee on the CCP”) on January 25, 2024, targets certain biotechnology companies that are headquartered in foreign adversary countries. The Act prohibits U.S. government agencies from acquiring biotechnology equipment or services produced or provided by a biotechnology company of concern. Additionally, there have been calls on the U.S. Department of Defense, Commerce, and Treasury to investigate biotechnology company WuXi Apptec and its subsidiary WuXi Biologics. Members of our International Trade and Government Relations practices have recently authored this thought leadership article which summarizes the proposed Act's background, goals, targets, and more. Please be sure to click the link below to learn more.

The BIOSECURE Act, introduced on January 25 by the House Select Committee on China, targets certain biotechnology companies that are headquartered in foreign adversary countries. The Act prohibits U.S. government agencies from acquiring biotechnology equipment or services produced or provided by a biotechnology company of concern. Our International Trade and Government Relations team authored this article which summarizes the proposed Act's background, goals, targets, and more. Please click the link below to learn more.

The Biotechnology Industry Organization (BIO) supports the BIOSECURE Act to prevent foreign biotech companies from accessing U.S. funding, emphasizing national security. WuXi AppTec, facing scrutiny and alleged unfair targeting, exits BIO. Amid concerns over ties to Chinese officials, U.S. legislators advance measures targeting certain Chinese biopharma firms. You can read more below. https://lnkd.in/gm4QThD4

I am thrilled to share that my forum post "House Blocks Chinese Biotech: Great Wall Built, but Who Guarded the Supply Chain?" has been published on the St. Thomas Law Review website. In this post, I explore the potential effects of the Biosecure Act on supply chains in the biotechnology industry. Check it out below!

Breaking News: BIO Parts Ways with WuXi AppTec Amid U.S. Security Concerns! - 💼 The U.S. Biotechnology Innovation Organization (BIO) and WuXi AppTec, a Chinese biotech giant, have cut ties amidst security concerns stemming from the pending U.S. legislation specifically targeting Chinese biotech companies. - 🇺🇸 BIO emphasized its commitment to U.S. policy makers and stated that it supports the BIOSECURE Act, which is aimed at protecting the personal health and genetic data of Americans from foreign adversaries. - 🧬 WuXi AppTec, a leading CDMO headquartered in China, said that it did not pose a security threat and stated that it voluntarily terminated its membership with BIO, because of misleading allegations. - 📉 The severance has caused significant investor worry, leading to major sell-offs of WuXi AppTec shares. - 🌐 Strains in U.S.-China relations are evident as political tensions spill over into the biotech industry, drastically impacting global markets and investor sentiment. Stay up to date and read more: https://lnkd.in/ge38BChq #USChinaRelations #BIO #WuXiAppTec #biotech #BIOSECUREAct #globalmarkets #marketshares #investorinsights

The BIOSECURE Act aims to restrict U.S. contracts with certain Chinese biotech companies, addressing national security concerns. This could significantly impact the biotech sector, affecting supply chains and partnerships. Companies should monitor the legislative progress and prepare for changes by evaluating current vendor relationships and exploring alternatives. Check out our Blog Post from OGC Partner Elizabeth Smith https://lnkd.in/ePVmXPqJ #BioTechLaw #BIOSECUREAct #NationalSeccurity #USBiotech

A great overview of a piece of potential legislation that will significantly impact #lifesciences, along with some practical immediate steps companies can take to prepare for it, by my partner Elizabeth Dana Smith.